Compare Medpace Holdings Inc (MEDP) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PAGSEG Inc — how do they compare? Medpace Holdings Inc trades at $532.42 (market cap $15.08B), while PAGSEG Inc trades at $9.57 (market cap $2.60B). The key difference: Medpace Holdings Inc is far larger — about 5.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.19% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PAGS | |
|---|---|---|
Market Cap | $15.08B | $2.60B |
Sector | Technology | Technology |
52-Week High | $620.59 | $12.00 |
52-Week Low | $308.88 | $7.75 |
Enterprise Value | $14.55B | $10.23B |
Dividend Yield | — | 11.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
PAGS trades at $9.29, up 2.77% today, with bearish technical signals but strong fundamentals including a P/E of 6.4 and net income margin of 10.4%. Recent earnings showed a Q1 2026 miss at $0.39 EPS versus $0.40 expected, while Q4 2025 beat expectations. The company maintains robust cash flow from operations of $7.56B in 2025 and declared a $0.26 dividend for H1 2026, payable June 1, 2026.
The stock presents a value opportunity with low valuation multiples and solid profitability, though technical weakness and mixed earnings create near-term uncertainty. Risks include Brazilian macroeconomic sensitivity and competitive pressures, but analyst consensus is strongly bullish with 62.5% buy ratings, suggesting upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
